

mRNA-1273-P920, Post-marketing safety of elasomeran/davesomeran and andusomeran vaccines in the United States

First published: 27/10/2023

Last updated: 15/05/2024

Study

Ongoing

Administrative details

PURI

<https://redirect.ema.europa.eu/resource/106695>

EU PAS number

EUPAS106694

Study ID

106695

DARWIN EU® study

No

Study countries

United States

Study description

This is a retrospective cohort study of adults and children identified in US administrative claims data, a source of secondary data. The observed rates of AESI among patients who receive at least one dose of the Elasomeran/Davesomeran and Andusomeran vaccine will be compared to two concurrent comparator groups utilizing two separate cohorts.

Study status

Ongoing

Contact details

Study institution contact

Clinical Trial Disclosure ModernaTX

Study contact

cttd@modernatx.com

Primary lead investigator

Clinical Trial Disclosure ModernaTX

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

31/01/2022

Study start date

Actual:

14/04/2023

Data analysis start date

Actual:

14/04/2023

Date of interim report, if expected

Actual:

15/09/2023

Date of final study report

Planned:

15/09/2024

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

ModernaTX Inc

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Main study objective:

The overarching aim of this study is to characterize the safety of the Omicron-containing bivalent SARS-CoV-2 mRNA-1273 booster vaccine as used in routine clinical practice.

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Name of medicine

Spikevax

Name of medicine, other

Spikevax bivalent, Spikevax XBB.1.5

Population studied

Age groups

Infants and toddlers (28 days – 23 months)

Children (2 to < 12 years)
Adolescents (12 to < 18 years)
Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Estimated number of subjects

10000000

Study design details

Outcomes

Number of Participants With Adverse Events of Special Interest (AESI)

Data analysis plan

Primary Cohort Analysis For each patient, a propensity score (PS) will be calculated to estimate the probability of receiving a dose of the elasmomeran/davesomeran or andusomeran vaccine conditional on measured covariates. The PS will be calculated utilizing inverse probability of treatment weighting (IPTW).

Data management

Data sources

Data sources (types)

[Administrative data \(e.g. claims\)](#)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No